Abigail Brooks, MA

GLP-1 RA use was linked to a significant survival benefit and reduced risk of iron deficiency anemia in patients with celiac disease.

Real-world data suggest adding fibrates to first-line UDCA incurs several clinical benefits, including reductions in spontaneous bacterial peritonitis and hospitalizations.

Despite bearing a greater obesity burden, Black, Hispanic, and American Indian/Native individuals are underrepresented in GLP-1 RA RCTs for weight loss.

Findings from a prespecified analysis of the phase 3 MAESTRO-NASH trial highlight resmetirom’s consistent benefit with background SGLT2i or GLP-1 RA treatment.

Findings suggest having GERD incurs an 18% greater risk of a new AUD diagnosis, presenting an opportunity to discuss alcohol use with patients.

View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.

The ACP Performance Measurement Committee reviewed 5 performance measures for CRC screening, ultimately only supporting 1 of them.

Findings from the quality improvement study provide real-world data supporting empirical donor exclusion and multiple-dose capsule FMT to increase CDI cure rates.

The FDA approved expanded indications for adalimumab-aaty (Yuflyma) and its unbranded version to include the treatment of adolescent HS and pediatric UV.

Final results from APPLAUSE-IgAN demonstrate iptacopan’s superiority versus placebo for slowing IgAN progression and will be used to support its full approval.

The phase 3 data reinforce iptacopan’s safety and efficacy in C3G and support its recent US Food and Drug Administration approval for this indication.

The decision updates the indication statements for ulcerative colitis and Crohn’s disease to allow use in patients who have received ≥ 1 approved systemic therapy.

The sBLA for insulin human Inhalation Powder in children and adolescents with type 1 or type 2 diabetes was assigned a PDUFA target action date of May 29, 2026.

Increases in short-term kidney function decline were observed following post-COVID-19 vaccination gross hematuria in individuals with IgA nephropathy.

LUCENT-3 open-label extension study data establish mirikizumab-mrkz (Omvoh) as the first and only IL-23p19 to show sustained long-term outcomes in UC through 4 years.

High intake of both sugar-sweetened beverages and low- or non-sugar-sweetened beverages was linked to greater MASLD risk.

The Q3 recap for gastroenterology spotlights key FDA decisions, new AGA gastroparesis guidelines, and other top GI news and research.

The approval is supported by data from the INTEGUMENT-PED phase 3 trial, the INTEGUMENT-OLE long-term extension study, and a phase 1 pharmacokinetic study.

The Q3 recap for hepatology spotlights key FDA news, the withdrawal of OCA for PBC, and notable hepatic research from the past few months.

The Q3 recap for nephrology spotlights key FDA decisions, new KDIGO IgA nephropathy guidelines, and other top renal news and research.

Read about new AGA gastroparesis guidelines, GI FDA news, and more.

Read about hepatic FDA news, the voluntary withdrawal of obeticholic acid for PBC, new trial data for a potential AATD drug, and more.

Check out renal FDA news, new KDIGO guidelines on IgAN and IgAV management, research about hypertensive kidney disease, and more.

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

Denecimig may offer a prophylaxis bleed treatment option for a range of patients across dosing frequencies, age groups, and condition severity.

The resubmission is based on results from 5 randomized clinical trials in the ONWARDS type 2 diabetes phase 3a program.

The approval of the selectively targeted somatostatin receptor type 2 agonist is supported by data from the phase 3 PATHFNDR-1 and PATHFNDR-2 trials.

The extended indication includes children 1 to < 5 years of age with homozygous familial hypercholesterolemia.

Both ACOG and AAP have released statements disagreeing with the FDA label change for acetaminophen to reflect autism risk in children if used during pregnancy.

Findings from an analysis of GBD 2021 data highlight increases in the absolute number of ASCVD cases and deaths among the working-age population.